CRL Logo

Charles River Laboratories International, Inc. (CRL) 

NYSE
Market Cap
$9.5B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
440 of 960
Rank in Industry
23 of 52

Largest Insider Buys in Sector

CRL Stock Price History Chart

CRL Stock Performance

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also …

Insider Activity of Charles River Laboratories International, Inc.

Over the last 12 months, insiders at Charles River Laboratories International, Inc. have bought $0 and sold $14.41M worth of Charles River Laboratories International, Inc. stock.

On average, over the past 5 years, insiders at Charles River Laboratories International, Inc. have bought $1.28M and sold $33.91M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,322 shares for transaction amount of $248,298 was made by Girshick Birgit (Corporate Executive VP & COO) on 2023‑11‑20.

List of Insider Buy and Sell Transactions, Charles River Laboratories International, Inc.

2024-11-07Saledirector
7,621
0.0151%
$216.17$1.65M-6.30%
2024-08-08SaleEVP, Corp Strategy & Develop
1,780
0.0034%
$199.36$354,861-3.05%
2024-08-01SaleChairman, President and CEO
25,000
0.05%
$250.00$6.25M-18.87%
2024-05-15Saledirector
332
0.0007%
$235.62$78,225-13.18%
2024-05-10SaleEVP, Corp Strategy & Develop
1,304
0.0025%
$226.97$295,969-10.97%
2024-03-08SaleCSVP&Chief Accounting Officer
808
0.0016%
$267.52$216,156-21.32%
2024-03-04SaleCSVP&Chief Accounting Officer
2,750
0.0054%
$261.05$717,890-18.75%
2024-02-29SaleEVP & Chief People Officer
5,000
0.0097%
$253.70$1.27M-17.01%
2024-02-29SaleCEVP, Disc & Safety Assessment
3,786
0.0073%
$253.45$959,545-17.01%
2024-02-22SaleCorporate Executive VP & CCO
4,050
0.0079%
$248.50$1.01M-13.96%
2024-02-15SaleEVP, Corp Strategy & Develop
838
0.0016%
$238.93$200,223-12.71%
2024-02-15SaleCEVP, Disc & Safety Assessment
5,882
0.0113%
$241.20$1.42M-12.71%
2023-12-14SaleEVP & Chief People Officer
5,526
0.0106%
$225.00$1.24M-4.35%
2023-11-30SaleEVP, Corp Strategy & Develop
1,850
0.0036%
$197.73$365,801+11.10%
2023-11-20PurchaseCorporate Executive VP & COO
1,322
0.0025%
$187.82$248,298+14.37%
2023-11-14PurchaseChairman, President and CEO
5,620
0.0109%
$178.05$1M+21.69%
2023-11-09SaleEVP, Corp Strategy & Develop
9,128
0.0182%
$173.48$1.58M+28.79%
2023-08-24Purchasedirector
1,000
0.0019%
$198.79$198,786+8.50%
2023-08-10SaleEVP, Corp Strategy & Develop
700
0.0014%
$216.52$151,564-1.30%
2023-08-10SaleCSVP&Chief Accounting Officer
1,471
0.0029%
$216.54$318,530-1.30%

Insider Historical Profitability

5.8%
FOSTER JAMES CChairman, President and CEO
188251
0.3681%
$185.70684+4.13%
WALLMAN RICHARD Fdirector
0
0%
$185.70413+7.27%
Girshick BirgitCorporate Executive VP & COO
44449
0.0869%
$185.70113
GILLETT NANCYCorporate Executive VP
11034
0.0216%
$185.70141+0.49%
Ho John CSenior Vice President
8950
0.0175%
$185.7010+15.04%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$1.64B11.746.05M+1.11%+$17.93M0.03
BlackRock$1.4B10.045.17M+0.2%+$2.82M0.03
State Street$567.4M4.072.09M+1.67%+$9.3M0.02
KAYNE ANDERSON INVESTMENT MANAGEMENT LLC$508.74M3.651.88M+7.09%+$33.7M1.18
ClearBridge Investments$409.98M2.941.51M+3.07%+$12.21M0.33
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.